A Finnish bioprinting firm is aiming to revolutionise the manufacture of personalised drugs and human ‘spare parts’ including kidneys, on the back of new investment.
Brinter, based in Turku, has raised €1.2M in seed funding to accelerate its 3D printing bioscience research and manufacturing for a range of uses.
It will use the capital to expand its operations in Europe and the US, as part of its stated mission to “put bioprinting within reach of every pharmaceutical company, hospital, university and research centre”.
Medical research facilities and universities often rely on traditional methods of discovery in the research of new drugs, understanding diseases, and finding medical ways to help people, Brinter says.
It believes its “modular multi-material 3D bioprinting solution” can improve the productivity of the scientific discovery process and bio-manufacturing. It can also be easily scaled up, the company adds.
Partly, it seeks to save more lives through more personalised treatment and the production of “spare parts” such as hearts and kidneys.
The seed funding round was led by early-stage VC Innovestor.
Brinter CEO Tomi Kalpio says: “We are excited to have the backing of Innovestor who can help us accelerate the development of our operational capabilities and scale in new geographies.
“Bioprinting has the capability to rapidly unlock the opportunities behind long-running but unrealised science and research, and plays a key role in pushing the frontier of medical science. This will result in an improved quality of life for patients through the expansion of more personalised treatment and the ongoing development of bioprinted “spare parts” that can save lives.”
Brinter’s customers include bio and pharma firms, such as Nanoform; and research organisations VTT, BEST group at the University of Glasgow, Johannes Gutenberg University of Mainz, the University of Oulu and the University of Helsinki.
Seppo Vainio, a professor of developmental biology and research director of the Kvantum Institute at the University of Oulu, says: “The printing of a new kidney for a transplant patient from programmed stem cells is a highly promising opportunity and could be realised already within this decade.
“There is a worldwide need for kidney transplants due to the rising incidence of diabetes, for example. Even the COVID-19 disease can lead to acute kidney failure, so there’s a great need for printed organ transplants and we look forward to the achievements that we will be able to reach using Brinter.”
Also working with Brinter is Jari Koistinaho, a professor of regenerative medicine at the University of Eastern Finland and director of the neuroscience centre at the University of Helsinki.
He says: “I am extremely excited to continue our 3D brain printing project with Brinter. The brain is an extremely vulnerable organ and target of various incurable diseases with the highest societal impact.
“Combined with two other rapidly-developing technologies – stem cells and biomaterials – 3D-bioprinting will soon provide us with fine-tuned human mini-brains and brain prosthetics, thereby deepening our understanding of the human mind and our ability to combat serious brain disorders.”
Brinter launched its first product in 2019 and is currently active in over 10 countries, including Germany and the UK.